BA1302 for advanced solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer that has spread or cannot be removed by surgery
- Your cancer has gotten worse after standard treatment, or you cannot tolerate standard treatment, or there is no standard treatment available
- You can provide a sample of your tumor for testing
- You are able to perform daily activities without much help (ECOG score 0 or 1)
- Your tumor can be measured on scans
- You have not had any other cancer in the last 5 years, except for certain early-stage skin or thyroid cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.